BIVDA Press Releases

05Apr

European Parliament endorses new Regulation on In Vitro Diagnostics

The European Parliament has endorsed the new Regulation on In Vitro Diagnostics (IVDR), a development welcomed by the British In Vitro Diagnostics Association (BIVDA).

A final vote was cast today (5 April 2017), bringing an eight year process to update the legislation, to its conclusion. The Regulation will be applicable to all IVD manufacturers who place their products within the European Economic Area and reflects the technological and scientific advances made since the implementation of the original IVD Directive (IVDD) 98/79/EC.

Commenting on the result, BIVDA’s Chief Executive Doris-Ann Williams MBE said:

“We are pleased that the European Parliament has endorsed the IVDR, which has been developed to further strengthen patient safety. There will be a considerable additional cost burden to the IVD industry to comply with this Regulation. However, the long development process to produce this Regulation has led to much uncertainty among IVD Manufacturers and we look forward to moving forward once it is published”.

BIVDA’s Chairman, Dr Simon Richards (Alere) added:

“BIVDA has been keeping members informed during the legislative process, and we will continue to work with industry to ensure that companies are fully prepared to meet the requirements of the new Regulation”.  

The official timings for transition start 20 days after the Regulation is published in the Official Journal. This is expected in early May, with an official transition starting date anticipated to start around June 1st. Following this, companies will have a five-year period to transition to compliance with the IVDR.

Notes to Editor:

BIVDA is the industry association for manufacturers and suppliers of IVD tests. We represent over 100 members, ranging from British start-up companies to UK subsidiaries of multinational corporations. BIVDA member companies employ more than 8,000 people in the UK, with total industry sales to the NHS of approximately £900 million.

For further information, please contact External Affairs Manager Emma Thomas at emma@bivda.co.uk or 0845 6188224.  

Related

BIVDA Attends UN Meeting on Antimicrobial Resistance

Doris-Ann Williams MBE, Chief Executive of the British In Vitro Diagnostics Association (BIVDA), rep...

Read More >

BIVDA responds to the final report of the Accelerated Access Review

Doris-Ann Williams MBE, Chief Executive of BIVDA, has responded to the publication of the final repo...

Read More >

BIVDA, ABPI and CRUK release briefing on new arrangements for commissioning and funding of six molecular diagnostic tests for cancer

BIVDA, ABPI and CRUK have released a stakeholder briefing to clarify the new arrangements for commis...

Read More >

UK continues to lag behind the European market for in-vitro diagnostic expenditure

IVD Market Statistics Report 2017 highlights differences in total healthcare expenditure and wide va...

Read More >

BIVDA Response to 2017 Budget

The Chancellor of the Exchequer has today (22 November) delivered the Government’s 2017 Budget.

Read More >

BIVDA comment on Withdrawal Agreement and political declaration

Doris-Ann Williams, Chief Executive of BIVDA, comments on the announcement of the Withdrawal Agreeme...

Read More >